![John Leonard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Leonard
Amministratore Delegato presso
INTELLIA THERAPEUTICS, INC.
Patrimonio netto: 20 M $ in data 31/05/2026
Profilo
Attualmente, John M. Leonard ricopre la posizione di presidente, amministratore delegato e direttore di Intellia Therapeutics, Inc. Il dott. Leonard è anche SVP-Global Pharmaceutical Research & Development presso Abbott Laboratories e fa parte del consiglio di amministrazione di altre 6 società. Il dott. Leonard ha precedentemente occupato la posizione di Senior VP-Pharmaceuticals, Research & Development presso Abbott Laboratories, CSO, SVP-Pharmaceutical Research & Development presso AbbVie, Inc. e Senior Director-Clinical Research presso G.H. Besselaar Associates. John M. Leonard ha conseguito una laurea presso l'Università del Wisconsin e un dottorato presso la Johns Hopkins University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 1.185.775 ( 0,85% ) | 17 M $ | 31/05/2026 | |
IQVIA HOLDINGS INC 0,01% | 23/04/2026 | 16.946 ( 0,01% ) | 3 M $ | 31/05/2026 |
Posizioni attive di John Leonard
| Società | Posizione | Inizio |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Amministratore Delegato | 01/01/2018 |
| IQVIA HOLDINGS INC. | Direttore/Membro del Consiglio | 05/02/2015 |
Tyree & D’Angelo Partners Management LP
 Tyree & D’Angelo Partners Management LP Investment ManagersFinance Tyree & D'Angelo Partners invests in lower middle market companies located in the United States and Canada with revenues less than USD 50 million and EBITDA ranging from USD 1 - 5 million. The firm focuses on companies operating in the healthcare, consumer, and business services sectors. It provides financing for buyout stage capital requirements. The firm acquires controlling stake and also makes co-investments. | Investitore di Private Equity | - |
IFM Continua, Inc.
 IFM Continua, Inc. BiotechnologyHealth Technology Develops biotechnology products | Direttore/Membro del Consiglio | - |
IFM Cinque, Inc.
 IFM Cinque, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in biotechnology | Direttore/Membro del Consiglio | - |
IFM Quattro, Inc.
 IFM Quattro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology company | Direttore/Membro del Consiglio | - |
IFM Therapeutics LLC
 IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology Discovers and develops small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity and inflammatory disorders | Direttore/Membro del Consiglio | 13/09/2018 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Direttore/Membro del Consiglio | - |
3T Biosciences, Inc.
 3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Direttore/Membro del Consiglio | 25/10/2022 |
Precedenti posizioni note di John Leonard
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di John Leonard
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
83
Relazioni di 1° grado
17
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 17 |
|---|---|
Abbott Laboratories
 Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Chimerix, Inc.
 Chimerix, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for rare epilepsies, cancers and sleep disorders | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Quintiles Transnational Holdings, Inc.
 Quintiles Transnational Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical development services and commercial outsourcing services | Commercial Services |
AbbVie, Inc.
 AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vitae Pharmaceuticals LLC
 Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops small molecule compounds | Health Technology |
G.H. Besselaar Associates | |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tyree & D’Angelo Partners Management LP
Tyree & D’Angelo Partners Management LP Investment ManagersFinance Tyree & D'Angelo Partners invests in lower middle market companies located in the United States and Canada with revenues less than USD 50 million and EBITDA ranging from USD 1 - 5 million. The firm focuses on companies operating in the healthcare, consumer, and business services sectors. It provides financing for buyout stage capital requirements. The firm acquires controlling stake and also makes co-investments. | Finance |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology Discovers and develops small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity and inflammatory disorders | Health Technology |
IQVIA Holdings, Inc.
 IQVIA Holdings, Inc. BiotechnologyHealth Technology Provides outsourced clinical research and trial, mission critical information, technology, healthcare and patient engagement services | Health Technology |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology Operates as an immunotherapy company that develops next-generation and transformative therapies for the treatment of solid tumors and immune-mediated diseases | Health Technology |
IFM Cinque, Inc.
IFM Cinque, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in biotechnology | Commercial Services |
IFM Continua, Inc.
IFM Continua, Inc. BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
IFM Quattro, Inc.
IFM Quattro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as biotechnology company | Commercial Services |
